EyePoint, Inc. (Nasdaq: EYPT) announced it will host a conference call on March 4, 2026 to report fourth quarter and full-year 2025 financial results. The clinical-stage biopharmaceutical company is advancing its lead product DURAVYU™, a sustained delivery treatment for retinal diseases, with Phase 3 pivotal trials for wet age-related macular degeneration expected to yield topline data beginning mid-2026, and first patient dosing in diabetic macular edema trials expected in Q1 2026.

EyePoint announced the appointment of Michael Campbell as Chief Commercial Officer, bringing over 30 years of ophthalmology commercial leadership experience. Campbell previously led successful launches of major retinal disease products including Lucentis and Xiidra. He will oversee commercial strategy for DURAVYU, the company's Phase 3 investigational sustained-release treatment for wet AMD and DME, with topline data expected mid-2026.

EyePoint, Inc. granted non-statutory stock options to three new employees for up to 13,900 shares at an exercise price of $15.84 per share on January 15, 2026. The options vest over four years with a ten-year term. The company continues advancing its lead product DURAVYU in Phase 3 trials for wet AMD and DME, with data expected beginning mid-2026.

EyePoint announced progress on its lead product DURAVYU (vorolanib intravitreal insert) with Phase 3 wet AMD trials on track for data readout beginning mid-2026 and Phase 3 DME program first patient dosing expected in Q1 2026. The company completed enrollment of over 900 patients across wet AMD trials in 7 months and has approximately $300 million in cash runway into Q4 2027.

EyePoint received a positive recommendation from its Data Safety Monitoring Committee for ongoing Phase 3 trials of DURAVYU, a potential treatment for wet age-related macular degeneration. The trials remain on track, with topline data expected in mid-2026.

EyePoint Pharmaceuticals reported Q3 2025 financial results, highlighting progress on DURAVYU clinical trials for wet AMD and diabetic macular edema, completed an oversubscribed $172.5 million equity financing, and positioned for key data readouts in mid-2026.

EyePoint Pharmaceuticals plans to raise approximately $150 million through a public offering of 11 million common stock shares and pre-funded warrants, with proceeds intended to advance clinical development of DURAVYU for retinal diseases.

EyePoint Pharmaceuticals will participate in multiple healthcare investment conferences in September 2025, presenting its lead product DURAVYU, an investigational sustained delivery treatment for retinal diseases.

EyePoint Pharmaceuticals will host a conference call on August 6, 2025 to discuss Q2 financial results and highlight corporate developments, focusing on their lead product DURAVYU, an investigational sustained delivery treatment for retinal diseases.

EyePoint Pharmaceuticals completed enrollment for its Phase 3 clinical trials of DURAVYU, a potential sustained-delivery treatment for wet age-related macular degeneration, with over 800 patients enrolled across two trials and topline data expected in mid-2026.

EyePoint Pharmaceuticals granted stock options to seven new employees, allowing purchase of 63,900 shares at $9.84 per share, with options vesting over four years.

EyePoint Pharmaceuticals, a biopharmaceutical company focused on retinal diseases, announced the grant of stock options to seven new employees as inducement awards. The options have an exercise price of $5.72 per share and vest over four years.